Literature DB >> 27013651

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.

Candida Vitale1, Inhye E Ahn2, Mariela Sivina1, Alessandra Ferrajoli1, William G Wierda1, Zeev Estrov1, Sergej N Konoplev3, Nitin Jain1, Susan O'Brien4, Mohammed Farooqui2, Michael J Keating1, Adrian Wiestner2, Jan A Burger5.   

Abstract

Entities:  

Keywords:  autoimmune cytopenia; chronic lymphochytic leukemia; ibrutinib

Mesh：

Substances：

Year:  2016        PMID： 27013651      PMCID： PMC5013951          DOI： 10.3324/haematol.2015.138289

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

Review 1.  Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.

Authors:  Stefano Molica; Luciano Levato; Rosanna Mirabelli
Journal:  Leuk Lymphoma       Date:  2015-10-12

2.  Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.

Authors:  Jan A Burger; Michael J Keating; William G Wierda; Elena Hartmann; Julia Hoellenriegel; Nathalie Y Rosin; Iris de Weerdt; Ghayathri Jeyakumar; Alessandra Ferrajoli; Marylou Cardenas-Turanzas; Susan Lerner; Jeffrey L Jorgensen; Graciela M Nogueras-González; Gracy Zacharian; Xuelin Huang; Hagop Kantarjian; Naveen Garg; Andreas Rosenwald; Susan O'Brien
Journal:  Lancet Oncol       Date:  2014-08-20       Impact factor: 41.316

Review 3.  Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.

Authors:  Tadeusz Robak; Ewa Robak
Journal:  Expert Opin Investig Drugs       Date:  2012-05-22       Impact factor: 6.206

4.  Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia.

Authors:  Tom G Rider; Richard J Grace; Joel A Newman
Journal:  Br J Haematol       Date:  2015-07-20       Impact factor: 6.998

5.  Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.

Authors:  Sudhir Manda; Nancy Dunbar; Cynthia R Marx-Wood; Alexey V Danilov
Journal:  Br J Haematol       Date:  2015-02-25       Impact factor: 6.998

6.  Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.

Authors:  F R Mauro; R Foa; R Cerretti; D Giannarelli; S Coluzzi; F Mandelli; G Girelli
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

7.  Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance.

Authors:  Carol Moreno; Kate Hodgson; Gerardo Ferrer; Montse Elena; Xavier Filella; Arturo Pereira; Tycho Baumann; Emili Montserrat
Journal:  Blood       Date:  2010-08-24       Impact factor: 22.113

8.  Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Jan A Burger; Kristie A Blum; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Yun Shaw; Elizabeth Bilotti; Cathy Zhou; Danelle F James; Susan O'Brien
Journal:  Blood       Date:  2015-02-19       Impact factor: 22.113

9.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

10.  Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.

Authors:  K A Rogers; A S Ruppert; A Bingman; L A Andritsos; F T Awan; K A Blum; J M Flynn; S M Jaglowski; G Lozanski; K J Maddocks; J C Byrd; J A Woyach; J A Jones
Journal:  Leukemia       Date:  2015-10-07       Impact factor: 11.528
View more
  15 in total

Review 1.  A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia.

Authors:  Mazie Tsang; Sameer A Parikh
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

2.  Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.

Authors:  Paul J Hampel; Melissa C Larson; Brian Kabat; Timothy G Call; Wei Ding; Saad S Kenderian; Deborah Bowen; Justin Boysen; Susan M Schwager; Jose F Leis; Asher A Chanan-Khan; Eli Muchtar; Curtis A Hanson; Susan L Slager; Neil E Kay; Kari G Chaffee; Tait D Shanafelt; Sameer A Parikh
Journal:  Br J Haematol       Date:  2018-08-16       Impact factor: 6.998

3.  Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia.

Authors:  S Schliffke; N Akyüz; C T Ford; T Mährle; T Thenhausen; A Krohn-Grimberghe; S Knop; C Bokemeyer; M Binder
Journal:  Leukemia       Date:  2016-05-25       Impact factor: 11.528

Review 4.  Managing toxicities of Bruton tyrosine kinase inhibitors.

Authors:  Andrew Lipsky; Nicole Lamanna
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 5.  Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

Authors:  Christopher Pleyer; Adrian Wiestner; Clare Sun
Journal:  Leuk Lymphoma       Date:  2018-05-15

Review 6.  Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.

Authors:  Iris de Weerdt; Suzanne M Koopmans; Arnon P Kater; Michel van Gelder
Journal:  Haematologica       Date:  2017-08-03       Impact factor: 9.941

7.  Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.

Authors:  M Montillo; S O'Brien; A Tedeschi; J C Byrd; C Dearden; D Gill; J R Brown; J C Barrientos; S P Mulligan; R R Furman; F Cymbalista; C Plascencia; S Chang; E Hsu; D F James; P Hillmen
Journal:  Blood Cancer J       Date:  2017-02-03       Impact factor: 11.037

8.  Chronic Lymphocytic Leukemia Presenting as a Subcortical Watershed Infarct.

Authors:  Mridul Gupta; Divita Singh; Patrick Lee; Sandhya Kadiyam
Journal:  Case Rep Hematol       Date:  2019-01-09

9.  Refractory Autoimmune Cytopenias Treated With Venetoclax.

Authors:  Max J Gordon; Edward Maldonado; Alexey V Danilov
Journal:  Hemasphere       Date:  2019-06-04

Review 10.  Chronic lymphocytic leukemia treatment algorithm 2018.

Authors:  Sameer A Parikh
Journal:  Blood Cancer J       Date:  2018-10-03       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.